Upload
neil-montgomery
View
261
Download
0
Tags:
Embed Size (px)
Citation preview
Reasons to Choose TaiwanUBI Asia in Partnership with UBI
Chang Yi Wang, PhDFounder, UBI
Chairperson, UBI Asia
Functional
Antigenics
UBI / UBI Asia
Molecular
Design of
Functional
Antigens
Adjuvant &
Formulation
Technologies
UBITh ®
Technology
Synthetic
Peptide
Technologies
Antigenic
Combinatorial
LibraryCyt
oto
xic
T
Lym
ph
ocy
te
Neu
tral
izat
ion
An
tib
od
ies
Vaccines andImmunotherapeutics
Immunodiagnostics TherapeuticMonoclonal Antibodies
AntibodyDeimmunization
Core Technology
Vaccines & ImmunotherapeuticsVaccines & Immunotherapeutics
Animal Health Products Human Health ProductsFunctional Antigenics
Canine AllergyTherapeutic
FMDVVaccine &
Diagnostics
LHRH Vaccinefor Boar Taint Removal &
Growth Promotion
LHRH Vaccine as Pet Contraceptive
LHRH Vaccineas Prostate Cancer
Therapeutic
HIV/AIDSVaccine & Therapeutic
AllergyTherapeutic
Alzheimer Disease Therapeutic
SARS Vaccine& Diagnostics
Product PortfoliosProduct Portfolios
Division of AIDS, NIAID, NIH, USA [HIV Immunotherapeutics]
NIAID, NIH, USA [Allergy Immunotherapeutic] NCI, NIH, USA [Prostate Cancer Immunotherapeutic] Baxter, USA BioMerieux (Lyon, France), formerly Organon Teknik
a of Akzo Nobel (Boxtel, Netherlands) Merial (Lyon, France) (JV of Merck and Aventis, larg
est animal health company in the world) The United Laboratories (Zhuhai, China) China Animal Husbandry Industry Corp. (Beijing, Ch
ina)
Business partners and Product Development Sponsors of UBI
Synergy: Traditional Pharma / Innovative Bio
Peptide Pilot Plant
Protein Drug Pilot Plant
Biologics Manufacture Plant
cGMPRoche
GSK
BioPharmaceuticsFoundation in
Taiwan
Toll Manufacture
Pharmaceutics Foundation in Taiwan
Compliance with FDA
International BioPharmaceutics
Company
Specialty Injectables
rowth
SurvivalcGMP
Pharmaceutical Plants
SynergyPharma / Bio
SynergyUBI / UBI Asia
Business Model
UBI UBI
技術轉移技術轉移
UBI AsiaUBI Asia
技術承接技術承接 & &
產品創新研發產品創新研發
Survival: Conservative Nurtures High Risk
cGMP cGMP ManufactureManufacture
•Acquire Roche & GSK cGMP plants:Acquire Roche & GSK cGMP plants: Chemical drugs, Chemical drugs, BiologicsBiologics
19991999 20022002
InnovativeInnovativeR & DR & D
•Peptide based:Peptide based:Vaccine & diagnosticsVaccine & diagnostics•Protein based:Protein based:Therapeutic monoclonal Therapeutic monoclonal antibodiesantibodies
FMDV Vaccine: Ko-T Con ® 口蹄安FMDV Diagnostics
From Genomics to Products Innovation Through Design
UBI Asia
The Vision:
Complete Replacement of Traditional Vaccineswithin 5 Years !!
UBITh® LHRH ImmunotherapeuticBoar Taint Removal Vaccine: Bota Con ® 寶特康Pet Contraceptive VaccineHuman Prostate Cancer Therapeutic
From Genomics to Products Innovation Through Design
UBI Asia
BotaCon ® 寶特康 :
An Immunotherapeutic to eliminate Boar Taint and promote pig growth and
Cattle
Therapeutic Monoclonal AntibodiesTherapeutic Monoclonal Antibodies
UBI Asia
Monoclonal Antibody Humanization (Murine Ab to Human Ab)
Hybridoma, Cesar Milstein & Georges Kohler
Chimeric mAb, Genentech
Fc
Fv
CDR grafting, PDL
1975 19941986
OKT3, 1986, 55 M USD
RePro, 1994, 447 M USD Rituxan, 1997, 298 M USD
Deimmunization, Biovation
1998
Identification of T cell and B cell
antigenic epitopes in Variable regions
Monoclonal Antibody Engineering
Well-Characterized Monoclonal Antibody (B4) Well-Characterized Monoclonal Antibody (B4) directed against HIV receptor complex for directed against HIV receptor complex for treatment of HARRT resistant AIDS patients treatment of HARRT resistant AIDS patients through entry inhibitionthrough entry inhibition
先導工廠
聯亞研發中心
產程發展 &原料藥生產
UBI Asia R & D
UBI Asia provides services to and collaborates with multiple commercial and research institutes
聯亞生產中心
聯亞 cGMP 廠
西藥 &生技藥品劑型生產
配方研發
臨床試驗產品登記
UBIUBI 國際國際臨床臨床 && 事業事業
中心中心
美國、美洲美國、美洲
台台灣灣
UBI AsiaUBI Asia研發研發 && 生產生產
中心中心
中國大陸中國大陸
歐洲歐洲
東南亞東南亞
日本、韓國日本、韓國
Vision: Designer Immunological Products for the treatment, prevention, and diagnosis of
globally significant diseases
Synergy: UBI Asia / UBI
UBI AsiaUBI AsiaR & D CenterR & D Center
Basic Research
ProcessDevelopment
Field & Field & Clinical Trials Clinical Trials
UBIUBIMOEAMOEA NIHNIH
Reasons to Choose TaiwanUBI Asia in Partnership with UBI
• Taiwan government with policies to promote biotechnology
• Taiwan has diligent, entrepreneurial and well-educated human resources
• Operations can be cost effective when compared with the west
• Easy access to fast breaking first hand business information
• Access to huge China market due to similarity in language and cultural background
• Training and testing ground for worldmarket due to its extensive connections to the western world
Join us, and Welcome to Taiwan!